Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis†
| Autor: | Felipe Ferreira Pimentel, Dolores Martins Guerra, Renata Maria de Freitas Barros, Liliana Andrade Chebli, Pedro Duarte Gaburri, Leonardo Duque de Miranda Chaves, Alexandre Zanini, Julio Maria Fonseca Chebli |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Azathioprine Gastroenterology Inflammatory bowel disease Cohort Studies Young Adult Adrenal Cortex Hormones Internal medicine medicine Clinical endpoint Humans Immunology and Allergy Prospective Studies Prospective cohort study business.industry Remission Induction Odds ratio Middle Aged medicine.disease Ulcerative colitis Surgery Regimen Treatment Outcome Colitis Ulcerative Female business Immunosuppressive Agents Follow-Up Studies Cohort study medicine.drug |
| Zdroj: | Inflammatory Bowel Diseases. 16:613-619 |
| ISSN: | 1078-0998 |
| Popis: | Background: Studies assessing the efficacy of azathioprine (AZA) in steroid-dependent ulcerative colitis (SD-UC) are scarce. The purpose of this trial was to explore the efficacy of AZA in maintaining steroid-free remission in SD-UC patients and the factors associated with sustained response. Methods: In this observational cohort study, 42 subjects with SD-UC were recruited for AZA therapy during a 3-year period. AZA was adjusted for a target dose of 2–3 mg/kg/day. Steroid therapy was tapered off following a standardized regimen. The primary endpoint was the annual rate of steroid-free response to AZA. Secondary endpoints included clinical recurrence, yearly steroid dose, and safety of treatment. Results: On an intention-to-treat basis, the proportion of patients remaining in steroid-free remission at 12, 24, and 36 months was 0.55, 0.52, and 0.45, respectively. A significant decrease in the flare-ups rate and in requirement for steroids were observed during 3 years on AZA compared with the previous year (P = 0.000 for both). Patients with and without sustained response were comparable according to demographics, extent of disease, dose of AZA, steroids, and 5-aminosalicylate (5-ASA) use. Only disease duration |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text